| Literature DB >> 30401461 |
Katharina Danhauser1, Bader Alhaddad2, Christine Makowski3, Dorota Piekutowska-Abramczuk4, Steffen Syrbe5, Natalia Gomez-Ospina6, Melanie A Manning6, Anna Kostera-Pruszczyk7, Claudia Krahn-Peper8, Riccardo Berutti9, Reka Kovács-Nagy10, Mirjana Gusic2, Elisabeth Graf9, Lucia Laugwitz11, Michaela Röblitz12, Andreas Wroblewski12, Hans Hartmann13, Anibh M Das13, Eva Bültmann14, Fang Fang15, Manting Xu15, Ulrich A Schatz16, Daniela Karall17, Herta Zellner17, Edda Haberlandt18, René G Feichtinger19, Johannes A Mayr19, Thomas Meitinger20, Holger Prokisch21, Tim M Strom2, Rafał Płoski22, Georg F Hoffmann5, Maciej Pronicki23, Penelope E Bonnen24, Susanne Morlot25, Tobias B Haack26.
Abstract
ADP-ribosylation is a reversible posttranslational modification used to regulate protein function. ADP-ribosyltransferases transfer ADP-ribose from NAD+ to the target protein, and ADP-ribosylhydrolases, such as ADPRHL2, reverse the reaction. We used exome sequencing to identify five different bi-allelic pathogenic ADPRHL2 variants in 12 individuals from 8 families affected by a neurodegenerative disorder manifesting in childhood or adolescence with key clinical features including developmental delay or regression, seizures, ataxia, and axonal (sensori-)motor neuropathy. ADPRHL2 was virtually absent in available affected individuals' fibroblasts, and cell viability was reduced upon hydrogen peroxide exposure, although it was rescued by expression of wild-type ADPRHL2 mRNA as well as treatment with a PARP1 inhibitor. Our findings suggest impaired protein ribosylation as another pathway that, if disturbed, causes neurodegenerative diseases.Entities:
Keywords: ADPRHL2; ARH3; PARP; ataxia; cerebellar atrophy; neurodegeneration; neuropathy; posttranslational modification; ribosylation; seizure
Mesh:
Substances:
Year: 2018 PMID: 30401461 PMCID: PMC6218634 DOI: 10.1016/j.ajhg.2018.10.005
Source DB: PubMed Journal: Am J Hum Genet ISSN: 0002-9297 Impact factor: 11.025